한국지질동맥경화학회 학술대회

The session "Comprehensive Cardiovascular Prevention: CAC and Beyond," joint symposium by the American Society of Preventive Cardiology (ASPC) and the Korean Society of Lipid and Atherosclerosis (KSoLA), will explore the crucial role of Coronary Artery Calcium (CAC) in the prevention of Atherosclerotic Cardiovascular Disease (ASCVD), its clinical implications, and the role of imaging in cardiovascular prevention. Professor Khurram Nasir from Houston Methodist DeBakey Heart & Vascular Center will discuss the role of CAC scoring in the prevention of ASCVD. Professor Jang­Hoon Lee from Kyungpook National University will cover the clinical implications and limitations of CAC scoring. Additionally, Professor Sang-Eun Lee from Ewha Womans University will present on the role of imaging in cardiovascular prevention.

New treatments for traditional lipid markers associated with atherosclerosis, as well as for newly emerging lipid markers, are being developed. This session is designed to introduce these new treatments in the field of dyslipidemia. First, Professor Yu-Mi Kang and Professor Andre Zimerman from the Moinhos de Vento Hospital and College of Health Sciences, Brazil will present on clinical research of new agents targeting Lp(a) and TG. Additionally, Professor Kyung-Woo Park from Seoul National University College of Medicine will discuss the current status of the development of next-generation PCSK9 inhibitors. This session is expected to be very helpful in understanding the latest trends in the treatment of dyslipidemia.

In this special lecture, Professor Jae-Taek Kim, the board of directors of the Korean Society of Lipid and Atherosclerosis and a distinguished professor at Chung-Ang University College of Medicine, will present the culmination of his decades-long research. He will offer an in-depth lecture on the influence of Insulin-like Growth Factor (IGF)-1 signaling pathways on key characteristics of heart disease, including myocardial hypertrophy, cell death, aging, fibrosis, and electrical remodeling. This promises to be a highly insightful and enriching experience, shedding light on critical aspects of cardiovascular health.

This session, titled "New therapeutic strategies for metabolic diseases," will explore the latest treatment strategies and research findings for metabolic diseases. Professor Véronique A. Lacombe from Oklahoma State University will present on "Cardiac-specific SERCA overexpression improves cardiac and systemic glucose metabolism during diabetes: novel therapeutic targets," highlighting innovative therapeutic targets to improve glucose metabolism. Professor Won Kim from Seoul National University will present “ADAMTS4 elicits myeloid-derived immune cell recruitment and liver fibrogenesis in metabolic dysfunction-associated steatotic liver disease,” providing the therapeutic potential of ADAMTS4 in hepatic fibrosis. Professor Il Minn from University of Texas Southwestern Medical Center will discuss "Cardiovascular toxicity induced by radiation therapy and introduction of radiopharmaceutical therapy," shedding light on the cardiovascular side effects of radiation therapy and the potential of radiopharmaceutical therapy. This session promises to provide valuable insights into the latest trends and novel approaches in the treatment of metabolic diseases.

Lipoprotein(a) is a significant genetic risk factor for cardiovascular diseases, and guidelines recommend it be measured at least once in a lifetime for all adults to assess individual cardiovascular risk. Professor Børge Nordestgaard from the University of Copenhagen will deliver a lecture in this session. Professor Nordestgaard has played a pivotal role in the recognition of lipoprotein(a) as a risk factor for cardiovascular disease, aortic valve calcification, and stenosis through his extensive research on biochemical and genetic biomarkers. His work has significantly contributed to guidelines for managing dyslipidemias, including lipoprotein(a), triglycerides, and familial hypercholesterolemia. This session will provide an overview of key findings from observational and genetic studies on lipoprotein(a) in the context of cardiovascular disease, discuss clinical applications, and explore novel therapeutic targets involving lipoprotein(a).

The joint symposium with the Japan Atherosclerosis Society (JAS) will explore cutting-edge advancements in incretin-based multi-agonist therapies for cardiometabolic disorders. Three distinguished speakers will share their expertise on this crucial topic. Professor Yasuo Terauchi from Yokohama City University, Japan, will discuss the efficacy and safety of tirzepatide, a GIP and GLP-1 dual agonist, in type 2 diabetes. Professor Chang Hee Jung from the University of Ulsan, Republic of Korea, will delve into the implications of GLP-1/GIP therapies for atherosclerotic cardiovascular disease (ASCVD). Professor Yong-ho Lee from Yonsei University, Republic of Korea, will elucidate the potential mechanisms underlying GLP-1/GIP therapies. This session promises to provide a comprehensive overview of the latest developments in multi-agonist therapies, their clinical applications, and their potential to revolutionize cardiometabolic disease treatment.

Dr. R. Scott Wright is a Professor of Medicine and a consultant in cardiology at the Mayo Clinic in Rochester. Dr. Wright focuses his research on acute coronary syndrome, dyslipidemia, type 2 diabetes, and valvular heart disease. He is a renowned international leader and an active clinical investigator of PRINCESS, CRISP and ORION programs. At ICoLA 2024, he will deliver a keynote lecture entitled, “Recent advances in the treatment of dyslipidemia with PCSK9 therapy and a look into potential new options in the next 10 years”.

In this special lecture, Professor Sung Nim Han from Seoul National University will deliver a lecture on the topic "Dissecting dietary approaches targeting lipid biomarkers." Professor Han, former president of the Korean Nutrition Society and the Korean Society of Clinical Nutrition, will systematically explore the impact of various dietary factors on lipid biomarkers. The lecture will include in-depth discussions on how dietary management affects lipid biomarkers in the bloodstream, contributing to a deeper understanding of its positive and negative impacts on health. Moreover, Professor Han will share insights based on extensive research experience and discuss future clinical application potential and vision.

The joint symposium with the Taiwan Society of Lipids & Atherosclerosis (TSLA) will delve into the pivotal role of remnant cholesterol in the statin era. We will explore its impact on cardiometabolic health, cardiovascular disease, and treatment options, with a focus on Asian populations. Professor Jun Hwa Hong from Eulji University will begin with "How does remnant cholesterol related to cardiometabolic multimorbidity" highlighting the links between remnant cholesterol and various cardiometabolic conditions. Next, Dr. Donna Shu-Han Lin from Shin Kong Wu Ho­Su Memorial Hospital will present "Epidemiologic evidence of hypertriglyceridemia or remnant cholesterol on cardiovascular disease" providing key epidemiological insights. Finally, Professor Youngwoo Jang from Gachon University will discuss "Treatments targeting remnant cholesterol or hypertriglyceridemia in Asians: do we have an option?" offering a detailed analysis of therapeutic strategies for Asian patients. Join us to gain a comprehensive understanding of remnant cholesterol in contemporary cardiovascular care.